Amgen Inc. — Sponsor Intelligence | 81 EU Trials

Filter these 81 trials by condition, phase, country and more.

Open in Search →

81 Registered trials

22 Recruiting

51 Completed trials

26 Countries active

73 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 42 Phase II: 12 Phase I/II: 4 Phase IV: 2 Phase I: 8 Phase I (Other): 9 Phase I (FiH): 3 Other: 1

Oversight events:

10 serious breaches 29 temporary halts 1 urgent safety measure 6 corrective measures across 15 trials

View oversight register →

100%

51 of 51 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 11 Small cell lung cancer extensive stage 7 Obesity 3 Overweight 3 Ductal adenocarcinoma of pancreas 3 Breast cancer 3 Gastric cancer 3 Prostate cancer 3 Ovarian cancer 2 Small cell lung cancer recurrent 2 Migraine 2 Osteogenesis imperfecta 2

Top IMPs

MARIDEBART CAFRAGLUTIDE 6 ROCATINLIMAB 6 TARLATAMAB 6 AMG 193 3 APREMILAST 3 BEMARITUZUMAB 3 AMG 732 2 BLINATUMOMAB 2 ERENUMAB 2 INEBILIZUMAB 2 OLPASIRAN 2 ROMIPLOSTIM 2

All trials — page 3

81 total

OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Phase III 22 countries OLPASIRAN
First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cance… Ended

2024-511021-58-00 Phase I (Other) 6 countries
A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended

2023-504363-17-00 Phase I (FiH) 4 countries AMG 193
Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101) Ended

2023-506794-35-00 Phase I (Other) 6 countries
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Phase III 17 countries
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended

2024-511837-37-00 Phase II 9 countries TARLATAMAB
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200) Ended

2023-508214-42-00 Phase III 8 countries DEXAMETHASONE
Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine Ended

2023-504930-23-00 Phase III 7 countries ERENUMAB
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specifi… Ended

2024-511798-31-00 Phase I (FiH) 8 countries
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300… Ended

2023-506541-39-00 Phase I 6 countries
Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (D… Halted

2024-515903-21-00 Phase I (Other) 6 countries
A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer Halted

2024-511965-13-00 Phase I (Other) 1 country
A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted

2023-506136-32-00 Phase I/II 7 countries BLINATUMOMAB
A Phase 1/2 Study of AMG 193 in Combination with IDE397 in Subjects with Advanced MTAP-null Solid Tumors Ended

2023-504364-42-00 Phase I/II 2 countries AMG 193; IDE397
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended

2022-502867-39-00 Phase I 3 countries
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended

2022-502620-49-00 8 countries
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Phase II 17 countries
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended

2022-501586-50-00 Phase III 10 countries
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Phase III 14 countries ROCATINLIMAB
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Phase III 11 countries ROCATINLIMAB
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Phase III 12 countries ROCATINLIMAB
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Witho… Ended

2023-510470-13-00 Phase II 5 countries MARIDEBART CAFRAGLUTIDE
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Phase III 12 countries BEMARITUZUMAB
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Phase I/II 15 countries BEMARITUZUMAB

Showing 49–72 of 81 trials

← All sponsors A–Z